subject
breaking
biotech
news
hey
thought
might
want
take
look
gtha
could
genethera
become
next
darling
biotech
announce
collaborations
industry
giant
beckman
coulter
breaking
biotech
news
genethera
inc
collaborate
biotech
giant
beckman
coulter
inc
genethera
news
release
july
th
genethera
inc
otc
bb
gtha
molecular
biotech
company
located
wheat
ridge
co
granted
first
right
refusal
beckman
coulter
inc
nyc
bec
license
genethera
patented
technology
developing
live
animal
genetic
diagnostic
tests
significant
milestone
genethera
beckman
coulter
one
world
leading
manufacturers
biomedical
testing
systems
tests
supplies
collaboration
unite
expertise
beckman
coulter
cutting
edge
technology
genethera
dr
antonio
milici
ph
genethera
inc
genethera
provides
genetic
diagnostic
solutions
veterinary
agricultural
industries
future
plans
include
healthcare
industry
company
formed
realize
commercial
potential
molecular
diagnostic
assays
using
roche
f
pcr
technology
detect
presence
infectious
disease
blood
animals
particularly
live
animals
platform
enables
genethera
offer
tests
presently
available
technology
future
plans
include
infectious
disease
potentially
affecting
domesticated
livestock
well
wildlife
intended
human
consumption
priority
given
mad
cow
johne
foot
mouth
diseases
cattle
genethera
successfully
developed
ability
detect
mad
cow
disease
chronic
wasting
disease
cwd
also
known
mad
deer
elk
free
information
reguarding
stocks
e
mail
first
name
last
name
phone
number
view
full
report
view
full
report
company
genethera
inc
symbol
gtha
exchange
otc
bb
recent
price
outstanding
shares
mil
website
www
genethera
net
prior
st
case
mad
cow
u
beef
exports
us
valued
near
billion
export
dollars
since
lost
international
us
beef
ban
imposed
million
cattle
feedlots
u
million
cattle
slaughtered
u
annually
beckman
coulter
inc
leading
manufacturer
biomedical
testing
instrument
systems
tests
supplies
simplify
automate
laboratory
processes
spanning
biomedical
testing
continuum
pioneering
medical
research
clinical
trials
laboratory
diagnostics
point
care
testing
beckman
coulter
installed
systems
provide
essential
biomedical
information
enhance
health
care
around
world
company
based
fullerton
calif
reported
annual
sales
billion
percent
amount
generated
recurring
revenue
supplies
test
kits
services
information
visit
www
beckmancoulter
com
looking
forward
working
genethera
identify
commercial
applications
technology
chris
neary
general
manager
prion
business
center
beckman
coulter
inc
countries
around
globe
discovery
cow
mad
cow
disease
leads
immediate
slaughter
hundreds
even
thousands
cattle
wide
spread
fear
disease
spread
need
complete
disease
testing
dead
animals
costly
international
beef
recalls
common
since
mad
cow
testing
conducted
slaughter
process
genethera
live
animal
blood
test
could
lead
halting
mass
slaughters
widespread
panic
saving
industry
hundreds
millions
dollars
year
testing
single
blood
sample
genethera
could
end
need
slaughter
entire
herds
cattle
animals
disease
testing
saving
industry
hundreds
millions
dollars
year
currently
funded
institutional
money
manager
southern
california
genethera
plans
open
laboratories
worldwide
meet
exploding
bse
testing
demand
want
invest
dna
revolution
wait
customized
drugs
years
away
buy
shares
company
using
dna
diagnostic
work
forbes
good
genes
kerry
dolan
may
new
patented
tests
created
information
gleaned
genome
mapping
injected
new
life
higher
margins
near
business
billion
molecular
diagnostics
industry
expanding
annual
rate
according
consulting
firm
leomics
associates
emerson
n
j
genethera
gtha
making
mark
biotech
genethera
recently
teamed
biotech
giant
beckman
coulter
inc
first
market
blood
test
mad
cow
disease
live
cattle
ability
detect
numerous
infectious
diseases
utilizing
genetic
methods
blood
live
animal
first
market
blood
test
detecting
cwd
presently
developing
therapeutic
vaccine
cwd
mad
cow
disease
using
rna
interference
technology
currently
developing
blood
test
using
platform
breast
prostate
cancer
detection
strategic
partner
xpng
xpention
genetics
inc
genethera
could
end
beef
recalls
potentially
slaughter
millions
animals
around
globe
saving
industry
hundreds
millions
dollars
year
currently
funded
institutional
money
manager
southern
california
genethera
plans
open
laboratories
worldwide
handle
growing
bse
testing
demand
genethera
could
generate
revenues
million
every
cattle
tested
usa
alone
international
testing
figures
would
staggering
genethera
technology
genethera
business
based
integrated
technology
platform
itp
combines
proprietary
diagnostic
solution
called
gene
expression
assay
gea
tm
purivax
tm
system
analyzing
large
scale
dna
sequencing
first
part
platform
ongoing
development
molecular
diagnostic
assays
solutions
using
real
time
fluorogenic
polymerase
chain
reaction
f
pcr
technology
detect
presence
infectious
disease
blood
live
animals
second
part
itp
development
therapeutic
vaccines
using
rna
interference
technology
also
allows
efficient
effective
continuous
testing
management
treatment
animal
populations
facts
distinguish
technology
alternative
testing
management
methodology
available
agriculture
today
require
destruction
individual
animals
even
entire
herds
testing
data
analysis
processes
also
allow
us
separate
infected
clean
animals
also
gain
knowledge
vital
development
preventative
vaccines
genethera
inc
committed
providing
global
access
cutting
edge
biotechnology
services
fellow
scientists
academia
pharmaceutical
industry
biotechnology
industry
primarily
genethera
expertise
focuses
technology
relevant
animal
human
immunotherapy
genethera
dedicated
furnishing
dependable
high
quality
cost
effective
prompt
client
consulting
services
services
backed
cumulative
experiences
greater
years
research
development
government
industry
genethera
senior
scientists
genethera
develops
commercial
scale
implementation
adenovector
purification
process
support
rd
material
production
furthermore
genethera
evaluates
tests
commercially
available
expression
vectors
incorporates
vector
repertoire
technologies
well
established
within
repertoire
genethera
scientific
staff
genethera
uniquely
detect
treat
variety
diseases
animals
still
alive
company
provides
genetics
based
diagnostic
vaccine
solutions
meet
growing
demands
today
veterinary
industry
tomorrow
agriculture
healthcare
industries
company
organized
operated
continually
apply
scientific
research
effective
management
diseases
realize
commercial
potential
molecular
biotechnology
core
genethera
operation
ongoing
development
molecular
diagnostic
assays
using
real
time
fluorogenic
polymerase
chain
reaction
f
pcr
technology
uses
live
animal
blood
detect
presence
infectious
diseases
development
vaccines
blood
born
diseases
also
allows
efficient
effective
continuous
testing
management
treatment
animal
populations
facts
distinguish
technology
alternative
testing
management
methodology
available
agriculture
today
require
destruction
individual
animals
even
entire
herds
testing
data
analysis
processes
also
allow
us
separate
infected
clean
animals
also
gain
knowledge
vital
development
preventative
vaccines
date
genethera
successfully
developed
assay
ability
detect
mad
cow
chronic
wasting
disease
disease
affecting
elk
deer
north
america
diagnostic
assays
e
coli
ol
h
johnne
disease
final
stages
development
vaccines
e
coli
ol
h
johnne
disease
diseases
affecting
cattle
advanced
stages
development
future
company
plans
expand
assay
application
research
wide
range
diseases
animals
immediate
targets
mad
cow
hoof
mouth
west
nile
newcastle
genethera
detect
bse
using
companies
patented
live
animal
blood
test
evaluates
e
r
f
gene
sequence
e
r
f
gene
proven
decrease
dramatically
tse
infection
noticeable
live
animal
human
patent
gtha
holds
broad
based
detect
tse
diseases
including
mad
cow
bse
cattle
cwd
elk
deer
creutzfeld
jacobs
humans
company
patented
test
detect
diseases
faster
method
developed
marketplace
far
less
cost
test
also
used
mass
scale
using
roche
f
pcr
dna
analyzing
robotics
equipment
genethera
analyze
blood
samples
day
one
f
pcr
machine
single
technician
project
prove
highly
profitable
approx
per
test
wide
scale
commercialization
way
multi
billion
dollar
international
demand
commercial
mad
cow
testing
emerged
around
globe
japan
conducted
million
post
mortem
rapid
mad
cow
tests
last
year
alone
used
western
blot
developed
prionics
ag
swizterland
bio
rad
rapid
test
costs
dollars
per
test
importantly
tests
marketplace
detect
disease
animal
killed
testing
post
mortem
brain
tissue
exams
extremely
labor
intensive
costly
japan
spent
million
million
million
post
mortem
rapid
mad
cow
tests
genethera
simple
blood
test
collected
using
patented
field
collection
system
sample
mailed
lab
testing
company
also
stated
recent
k
currently
negotiations
strategic
testing
partners
believe
absorb
costs
commercializing
live
animal
mad
cow
test
management
dr
tony
milici
chairman
board
president
ceo
dr
milici
ph
experimental
hematology
medicine
surgery
receiving
degrees
university
rome
italy
stanford
university
specialties
include
molecular
biology
biotechnology
gene
therapy
molecularly
oncology
molecular
extensive
post
graduate
training
includes
fellowship
department
clinical
immunology
university
texas
anderson
cancer
center
visiting
fellow
university
rome
laboratory
cellular
immunology
biochemistry
among
post
graduate
activities
dr
milici
assistant
professor
medical
college
georgia
department
pharmacology
toxology
well
assistant
biochemist
department
molecular
pathology
university
texas
anderson
cancer
center
houston
tx
prior
founding
genethera
inc
dr
milici
president
ceo
genetrans
inc
based
augusta
ga
diagnostics
laboratory
dr
milici
genethera
realization
ambition
demonstrate
commercial
potential
molecular
biotechnology
dr
thomas
j
slaga
board
member
dr
slaga
ph
physiology
biophysics
undergraduate
degrees
biology
chemistry
since
dr
slaga
served
adjunct
professor
department
biochemistry
molecular
biology
university
colorado
health
sciences
center
located
denver
co
dr
slaga
career
steeped
research
development
roles
affiliations
concentrating
cancer
examples
include
chair
scientific
director
cancer
causation
prevention
amc
cancer
research
center
located
denver
co
director
professor
biochemistry
university
texas
anderson
cancer
center
science
park
research
division
located
smithville
tx
group
leader
research
staff
member
skin
carcinogenesis
tumor
promotion
biology
division
oak
ridge
national
laboratory
oak
ridge
tn
dr
slaga
blend
scientific
management
experience
lends
genethera
board
important
dimension
vis
vis
development
opportunities
mr
richard
w
bryans
jr
board
member
general
counsel
mr
bryans
attorney
law
denver
co
graduate
regis
university
business
administration
economics
mr
bryans
went
graduate
university
denver
college
law
practicing
law
denver
years
mr
bryans
provides
genethera
board
much
valued
legal
perspective
benefit
young
publicly
traded
company
additionally
company
able
take
advantage
mr
bryans
legal
experience
important
area
vaccine
licensing
integral
future
genethera
join
market
movers
mailings
click
find
tw
inc
hidden
forest
dr
sarasota
fl
disclaimer
publicly
distributed
email
report
otc
special
situations
report
publication
otc
growth
stock
watch
sponsored
advertisement
paid
advertising
issue
otc
growth
stock
watch
purport
provide
analysis
company
financial
position
way
construed
offer
solicitation
buy
sell
security
otc
growth
stock
watch
paid
advertiser
xpention
genetics
inc
featured
company
distribution
costs
report
new
subscribers
eighty
thousand
dollars
funded
tw
inc
effort
create
investor
awareness
xpention
genetics
inc
tw
inc
broker
dealer
investment
advisor
market
movers
otc
growth
stock
watch
otc
special
situations
report
geoffrey
eiten
considered
broker
dealer
though
investment
advisors
anticipated
report
generate
new
subscriptions
growth
stock
watch
neither
otc
growth
stock
watch
geoffrey
eiten
reviewer
analyst
received
compensation
report
expect
receive
unknown
amount
revenue
new
subscriptions
subscription
offer
contained
herein
report
including
opinions
expressed
statements
made
within
informational
advertising
purposes
construed
investment
advice
constitute
offer
sell
securities
soliciting
offer
buy
securities
state
jurisdiction
offer
sale
permitted
readers
consult
professional
investment
tax
portfolio
advisors
making
investment
decision
independently
verify
information
herein
information
used
prepare
report
believed
reliable
sources
representation
made
accuracy
completeness
information
investment
securities
carries
high
degree
risk
involves
risks
uncertainties
may
result
investors
losing
invested
capital
past
performance
guarantee
future
results
information
contained
herein
contains
forward
looking
statements
within
meaning
section
securities
act
section
e
securities
exchange
act
forward
looking
statements
based
upon
expectations
estimates
projections
time
statements
made
involve
risks
uncertainties
could
cause
actual
events
differ
materially
anticipated
forward
looking
statements
may
identified
use
words
expects
anticipates
estimates
believes
statements
indicating
certain
actions
may
could
might
occur
statements
express
involve
predictions
expectations
beliefs
plans
projections
objectives
goals
future
events
performance
may
forward
looking
statements
factors
could
cause
actual
results
differ
materially
include
limited
adverse
economic
conditions
intense
competition
lack
meaningful
research
results
inadequate
capital
termination
contracts
agreements
adverse
publicity
news
coverage
inability
carry
research
development
commercialization
plans
loss
retirement
key
executives
research
scientists
risks
detailed
company
reports
filed
securities
exchange
commission
complete
information
xpention
genetics
inc
available
website
securities
exchange
commission
http
www
sec
gov
copies
filings
may
read
without
charge
copies
obtained
prescribed
rates
public
reference
facilities
commission
fifth
street
nw
washington
dc
media
matrix
county
rd
dte
lake
mary
fl
e
mail
message
advertisement
solicitation
